TURIN. Which vaccines resist the variants? And what variants? These are questions that the whole scientific community is questioning, also in anticipation of a fourth wave that could be characterized by different forms of coronavirus that may not be covered by the current vaccines available.
For this reason, ASL is studying the efficacy of the Cuban vaccine Soberana plus on variants in Turin. The virology laboratory of Amedeo di Savoia, in collaboration with the infectious disease clinic led by virologist Giovanni Di Perri, is investigating Soberana plus’s ability to respond to variants.
“We are evaluating the ability of the sera of vaccinated Cuban subjects to counteract viral growth on in vitro cell cultures of the different variants – explains Valeria Ghisetti, director of the microbiology and virology laboratory of the Asl Città di Torino -. This type of analysis has already proved useful several times in predicting the effectiveness of vaccinations in preventing infection, symptomatic disease and disease in its most serious forms ».
Clinical trials in Cuba have shown 91.2% efficacy for symptomatic disease, 75.5% for infection and 100% for severe symptomatic disease and death. Encouraging data that the World Health Organization is also evaluating. The new study confirms the collaboration of Turin with Cuba that has been established since the first months of the infection with the sending of doctors from the Hanry Reeve Brigade to the city.